Yuvraj

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

In 2026, GSK, Amgen and other large pharma players restarted the M&A engine with targeted deals in immunology and oncology, signalling a shift toward science‑driven, portfolio‑balancing acquisitions. Explore how this new M&A cycle is reshaping the global pharma landscape.

Global pharma in Q1‑2026 is defined by pricing shocks in the US and Europe and a powerful growth shift to Asia. Explore how policy, margins, M&A and regional strategies are reshaping the pharmaceutical industry.

Egypt is stepping up its push to reinforce its pharmaceutical research landscape by deepening pharmaceutical cooperation with Takeda Pharmaceutical Company, aligning with a wider...

How Digital Dentistry Creates More Comfortable Patient Journeys For many people, visiting the dentist can still feel like a stressful experience. However, advances in digital...

The demand for online medicine delivery in India has grown rapidly as patients seek convenience without compromising on authenticity. With chronic digestive disorders on the...

Swiss drugmaker Roche has expanded its artificial intelligence infrastructure by deploying more than 2,100 NVIDIA chips, strengthening its computational capabilities to accelerate drug and...